Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of hemoadsorption with CytoSorb® on meropenem and piperacillin exposure in critically ill patients in a post-CKRT setup: a single-center, retrospective data analysis.
Intensive Care Med Exp
January 2025
Freie Universität Berlin and Humboldt-Universität Zu Berlin, Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Purpose: CytoSorb® (CS) adsorbent is a hemoadsorption filter for extracorporeal blood purification often integrated into continuous kidney replacement therapy (CKRT). It is primarily used in critically ill patients with sepsis and related conditions, including cytokine storms and systemic inflammatory responses. Up to now, there is no evidence nor recommendation for the use of CS filters in sepsis (22).
View Article and Find Full Text PDFAssociation between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study.
Geroscience
January 2025
Gerontopole, Clinical and Geroscience Research, Toulouse University Hospital, WHO Collaborating Center for Frailty, and Geriatric Training, Toulouse, France.
The aim of this study is to evaluate the association of systemic inflammation measured by plasma biomarkers with the change in cognitive function among participants from the Multidomain Alzheimer Preventive Trial (MAPT) exposed to the multidomain intervention (MI). Secondary analysis of the MAPT longitudinal data. MAPT is a randomized, placebo-controlled trial with 3 interventional groups (omega-3 only, MI only, omega-3 plus MI) and a control group.
View Article and Find Full Text PDFPrepartum supplementation of Ascophyllum nodosum meal or ethylenediamine dihydroiodide: Effects on colostrum yield and growth and health of dairy calves.
J Dairy Sci
January 2025
Department of Agriculture, Nutrition, and Food Systems, University of New Hampshire, Durham, NH 03824. Electronic address:
We aimed to evaluate the effects of prepartum supplementation of different I sources (Ascophyllum nodosum [ASCO] meal and ethylenediamine dihydroiodide [EDDI]) on colostrum yield of cows, and blood concentrations of glucose, BHB, and thyroid hormones and growth of dairy calves. Forty multiparous Holstein cows were blocked by lactation number and expected calving date and assigned to 1 of 4 treatments 28 d before parturition: (1) EDDI supplemented (11 mg/d) to a basal diet to meet the NRC (2001) I concentration of 0.5 mg of I/kg of DMI (control = CON [0 g/d of ASCO meal]; actual I concentration = 0.
View Article and Find Full Text PDFSupplemental palmitic acid and chromium propionate impact production responses during the immediate postpartum in multiparous dairy cows.
J Dairy Sci
January 2025
Department of Animal Science, College of Agriculture and Natural Resources. Electronic address:
Forty-eight multiparous Holstein cows were used in a randomized complete block design and assigned to one of 4 treatments in a 2x2 factorial arrangement of treatments to determine the effects of supplemental palmitic acid (C16:0) and chromium (Cr) on production responses of early-lactation cows. During the fresh period (FR; 1-24 d in milk), cows were fed one of 4 treatments: (1) a diet containing no supplemental C16:0 or Cr (CON); (2) diet supplemented with an 85% C16:0-enriched supplement (PA); (3) diet supplemented with Cr-propionate (CR); and (4) diet supplemented with a C16:0-enriched supplement and Cr-propionate (PACR). The C16:0-enriched supplement was added at 1.
View Article and Find Full Text PDFPan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
J Hepatol
January 2025
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, United States of America. Electronic address:
Background & Aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of different target tissues in relationship to change in intrahepatic triglyceride (IHTG) content.
Methods: This phase 2, single center, study randomized (1:1) 38 patients with T2D and MASLD to receive lanifibranor 800 mg or placebo for 24 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!